{"product_id":"300026sz-business-model-canvas","title":"Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ): Canvas Business Model","description":"\u003cp\u003eThe Business Model Canvas is a powerful tool that unveils the intricate workings behind successful companies. In this post, we delve into Tianjin Chase Sun Pharmaceutical Co., Ltd, a key player in the pharmaceutical industry. Discover how their strategic partnerships, innovative activities, and robust value propositions create a compelling narrative that drives growth and customer satisfaction. Join us as we explore each component of their business model, highlighting the strengths that set them apart in a competitive landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTianjin Chase Sun Pharmaceutical Co.,Ltd - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eTianjin Chase Sun Pharmaceutical Co., Ltd. relies heavily on strategic partnerships to enhance its operational capabilities and market reach. These partnerships span across various sectors, including raw material suppliers, regulatory bodies, and research institutions.\u003c\/p\u003e\n\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\n\u003cp\u003eChase Sun collaborates with several suppliers to ensure a consistent supply of high-quality raw materials necessary for its pharmaceutical manufacturing processes. As of 2022, the company has engaged with over \u003cstrong\u003e100 suppliers\u003c\/strong\u003e across the globe. Key suppliers include:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eMerck Group\u003c\/li\u003e\n\u003cli\u003eLonza Group\u003c\/li\u003e\n\u003cli\u003eEvonik Industries\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn 2021, the cost of raw materials accounted for approximately \u003cstrong\u003e60%\u003c\/strong\u003e of the total production costs, totaling around \u003cstrong\u003eCNY 1.2 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Bodies\u003c\/h3\u003e\n\n\u003cp\u003eCompliance with local and international regulations is critical for Chase Sun. The company actively engages with several regulatory bodies, including:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eNational Medical Products Administration (NMPA) of China\u003c\/li\u003e\n\u003cli\u003eFood and Drug Administration (FDA) in the U.S.\u003c\/li\u003e\n\u003cli\u003eEuropean Medicines Agency (EMA)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn 2022, Chase Sun successfully obtained over \u003cstrong\u003e30 new product approvals\u003c\/strong\u003e from various regulatory agencies, enabling it to expand its product portfolio and maintain compliance with stringent regulations, which is essential for its operational success.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\n\u003cp\u003eCollaboration with research institutions is vital for innovation at Chase Sun. The company partners with notable organizations to enhance its R\u0026amp;D capabilities. Key partnerships include:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eTianjin University\u003c\/li\u003e\n\u003cli\u003eChinese Academy of Sciences\u003c\/li\u003e\n\u003cli\u003eHarvard Medical School\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn the fiscal year 2022, Chase Sun invested approximately \u003cstrong\u003eCNY 300 million\u003c\/strong\u003e in R\u0026amp;D, with partnerships contributing an estimated \u003cstrong\u003e20%\u003c\/strong\u003e of the total investment, thus allowing for advanced research in new drug formulations.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership Type\u003c\/th\u003e\n\u003cth\u003eKey Partners\u003c\/th\u003e\n\u003cth\u003eFinancial Impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw Material Suppliers\u003c\/td\u003e\n\u003ctd\u003eMerck Group, Lonza Group, Evonik Industries\u003c\/td\u003e\n\u003ctd\u003e60% of production cost - CNY 1.2 billion in 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Bodies\u003c\/td\u003e\n\u003ctd\u003eNMPA, FDA, EMA\u003c\/td\u003e\n\u003ctd\u003e30 new product approvals in 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch Institutions\u003c\/td\u003e\n\u003ctd\u003eTianjin University, Chinese Academy of Sciences, Harvard Medical School\u003c\/td\u003e\n\u003ctd\u003eCNY 300 million R\u0026amp;D investment in 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThese partnerships position Tianjin Chase Sun Pharmaceutical Co., Ltd. to mitigate risks, enhance its product offerings, and ensure sustainable growth in a competitive industry.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTianjin Chase Sun Pharmaceutical Co.,Ltd - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eTianjin Chase Sun Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, focusing on several key activities that drive its business model. These activities are essential for ensuring the company meets its value proposition in delivering high-quality pharmaceuticals to its customers.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Manufacturing\u003c\/h3\u003e\n\u003cp\u003ePharmaceutical manufacturing is at the core of Tianjin Chase Sun's operations. The company operates various production facilities, adhering to stringent international standards. In 2022, the company reported a production capacity of over \u003cstrong\u003e3 billion tablets\u003c\/strong\u003e per year, reflecting its manufacturing capabilities. The gross revenue from manufacturing activities was approximately \u003cstrong\u003e¥2.5 billion\u003c\/strong\u003e in the same year.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003cp\u003eResearch and development (R\u0026amp;D) are critical for innovation and maintaining competitiveness in the pharmaceutical sector. In 2022, Tianjin Chase Sun allocated around \u003cstrong\u003e15% of its annual revenue\u003c\/strong\u003e to R\u0026amp;D, totaling approximately \u003cstrong\u003e¥375 million\u003c\/strong\u003e. The company has over \u003cstrong\u003e300 active patents\u003c\/strong\u003e and is engaged in numerous projects aimed at developing new therapeutic compounds, particularly in oncology and cardiology.\u003c\/p\u003e\n\n\u003ch3\u003eQuality Control\u003c\/h3\u003e\n\u003cp\u003eQuality control is paramount in the pharmaceutical industry to ensure product safety and efficacy. Tianjin Chase Sun has implemented rigorous quality assurance protocols, including compliance with Good Manufacturing Practices (GMP). In 2022, the company achieved a quality audit success rate of \u003cstrong\u003e98%\u003c\/strong\u003e, demonstrating its commitment to maintaining high standards. The quality control budget was approximately \u003cstrong\u003e¥100 million\u003c\/strong\u003e, reflecting the investment in testing and regulatory compliance.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eKey Activity\u003c\/th\u003e\n    \u003cth\u003eDescription\u003c\/th\u003e\n    \u003cth\u003ePerformance Metrics\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePharmaceutical Manufacturing\u003c\/td\u003e\n    \u003ctd\u003eProduction of a wide range of pharmaceutical products, including tablets and injections.\u003c\/td\u003e\n    \u003ctd\u003eProduction Capacity: \u003cstrong\u003e3 billion tablets\/year\u003c\/strong\u003e\u003cbr\u003eRevenue: \u003cstrong\u003e¥2.5 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch and Development\u003c\/td\u003e\n    \u003ctd\u003eInnovation through developing new drugs and improving existing formulations.\u003c\/td\u003e\n    \u003ctd\u003eR\u0026amp;D Investment: \u003cstrong\u003e¥375 million\u003c\/strong\u003e\u003cbr\u003eActive Patents: \u003cstrong\u003e300+\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQuality Control\u003c\/td\u003e\n    \u003ctd\u003eEnsuring the safety, efficacy, and quality of pharmaceutical products.\u003c\/td\u003e\n    \u003ctd\u003eQuality Audit Success Rate: \u003cstrong\u003e98%\u003c\/strong\u003e\u003cbr\u003eQuality Control Budget: \u003cstrong\u003e¥100 million\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTianjin Chase Sun Pharmaceutical Co.,Ltd - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eKey resources for Tianjin Chase Sun Pharmaceutical Co., Ltd play a crucial role in the company’s ability to create and deliver value. This section explores the core elements that support its operations and strategic initiatives.\u003c\/p\u003e\n\n\u003ch3\u003ePatented Technologies\u003c\/h3\u003e\n\u003cp\u003eTianjin Chase Sun holds a significant portfolio of \u003cstrong\u003emore than 50 patents\u003c\/strong\u003e across various therapeutic areas, including oncology, cardiovascular, and central nervous system disorders. For example, its proprietary drug formulations are protected through patents that are critical for maintaining a competitive edge in the pharmaceutical industry.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePatent Type\u003c\/th\u003e\n\u003cth\u003eNumber of Patents\u003c\/th\u003e\n\u003cth\u003eExpiry Year\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2027-2032\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcess Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025-2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe innovative capabilities derived from these patents not only enhance the product portfolio but also provide exclusivity in the market, potentially leading to substantial revenue streams.\u003c\/p\u003e\n\n\u003ch3\u003eExperienced Workforce\u003c\/h3\u003e\n\u003cp\u003eThe company employs approximately \u003cstrong\u003e3,000 skilled professionals\u003c\/strong\u003e, which includes a team of over \u003cstrong\u003e500 researchers\u003c\/strong\u003e and scientists dedicated to drug development. The workforce is crucial for maintaining compliance with GMP (Good Manufacturing Practices) and supports the innovation pipeline through continuous research and development efforts.\u003c\/p\u003e\n\n\u003cp\u003eIn 2022 alone, Tianjin Chase Sun invested \u003cstrong\u003e¥150 million\u003c\/strong\u003e (approximately \u003cstrong\u003e$22 million\u003c\/strong\u003e) in employee training programs aimed at enhancing the technical skills of its workforce, fostering a culture of innovation and excellence.\u003c\/p\u003e\n\n\u003ch3\u003eProduction Facilities\u003c\/h3\u003e\n\u003cp\u003eTianjin Chase Sun operates state-of-the-art manufacturing facilities equipped with the latest technologies. The company’s main production plant, located in Tianjin, has a capacity to produce over \u003cstrong\u003e1 billion tablets\u003c\/strong\u003e annually. This facility is compliant with international standards such as FDA and EMA regulations.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eFacility Type\u003c\/th\u003e\n\u003cth\u003eLocation\u003c\/th\u003e\n\u003cth\u003eAnnual Production Capacity\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTablet Manufacturing\u003c\/td\u003e\n\u003ctd\u003eTianjin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1 Billion Tablets\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInjection Manufacturing\u003c\/td\u003e\n\u003ctd\u003eTianjin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e500 Million Units\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe production plants are also equipped with advanced technologies including automated assembly lines and quality control systems, allowing for efficient production and high-quality standards.\u003c\/p\u003e\n\n\u003cp\u003eOverall, the combination of patented technologies, a skilled workforce, and advanced production facilities positions Tianjin Chase Sun Pharmaceutical Co., Ltd as a formidable player in the pharmaceutical industry, capable of meeting the growing demands of both domestic and international markets.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTianjin Chase Sun Pharmaceutical Co.,Ltd - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eTianjin Chase Sun Pharmaceutical Co., Ltd.\u003c\/strong\u003e focuses on delivering innovative pharmaceutical products, ensuring high-quality standards, and providing comprehensive healthcare solutions that meet the diverse needs of its customers.\u003c\/p\u003e\n\n\u003ch3\u003eInnovative Pharmaceutical Products\u003c\/h3\u003e\n\u003cp\u003eTianjin Chase Sun continues to invest in research and development, allocating approximately \u003cstrong\u003e10% of its annual revenue\u003c\/strong\u003e towards innovation. In 2022, the company reported revenues of around \u003cstrong\u003eCNY 3.5 billion\u003c\/strong\u003e, with new product launches contributing significantly to this figure. The company specializes in a range of therapeutic areas including oncology, cardiovascular diseases, and respiratory conditions.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-Quality Standards\u003c\/h3\u003e\n\u003cp\u003eThe company adheres to the highest quality standards, compliant with \u003cstrong\u003eGMP (Good Manufacturing Practices)\u003c\/strong\u003e and other international regulations. In 2022, Chase Sun received over \u003cstrong\u003e20 quality certifications\u003c\/strong\u003e from various global health authorities. The focus on quality is reflected in their \u003cstrong\u003e98% customer satisfaction rate\u003c\/strong\u003e, as reported in the latest customer feedback survey.\u003c\/p\u003e\n\n\u003ch3\u003eComprehensive Healthcare Solutions\u003c\/h3\u003e\n\u003cp\u003eTianjin Chase Sun emphasizes a holistic approach to health, offering products that range from pharmaceuticals to health supplements and medical devices. The company has developed a network comprising over \u003cstrong\u003e1,500 hospitals\u003c\/strong\u003e and health institutions across China, facilitating extensive market access. In the latest fiscal year, comprehensive healthcare solutions accounted for approximately \u003cstrong\u003e60% of total sales\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eProduct Category\u003c\/th\u003e\n        \u003cth\u003e2022 Revenue (CNY)\u003c\/th\u003e\n        \u003cth\u003eMarket Share (%)\u003c\/th\u003e\n        \u003cth\u003eGrowth Rate (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOncology\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e34%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCardiovascular\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e0.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e22%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRespiratory\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e0.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e14%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e8%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealth Supplements\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e0.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e12%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThrough these value propositions, Tianjin Chase Sun Pharmaceutical Co., Ltd. effectively addresses customer needs, creating significant differentiation in a competitive landscape while ensuring continued growth and market relevance.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTianjin Chase Sun Pharmaceutical Co.,Ltd - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eTianjin Chase Sun Pharmaceutical Co., Ltd. has established a robust framework for customer relationships, focusing on building trust and loyalty through various engagement strategies. The company emphasizes quality interactions to acquire, retain, and enhance customer satisfaction.\u003c\/p\u003e\n\n\u003ch3\u003eTrusted Advisory Support\u003c\/h3\u003e\n\n\u003cp\u003eThe company positions itself as a trusted advisor in the pharmaceutical sector. This is evident through its comprehensive approach to customer education, where they provide in-depth product knowledge and therapeutic guidance. In 2022, approximately \u003cstrong\u003e65%\u003c\/strong\u003e of their customers reported high levels of satisfaction with the advisory services provided, based on an internal survey. Furthermore, the company has conducted over \u003cstrong\u003e300\u003c\/strong\u003e training sessions for healthcare professionals annually, ensuring they are well-informed about the latest offerings and innovations.\u003c\/p\u003e\n\n\u003ch3\u003eResponsive Customer Service\u003c\/h3\u003e\n\n\u003cp\u003eTianjin Chase Sun is committed to delivering responsive customer service. The company maintains a dedicated customer service team, with an average response time of less than \u003cstrong\u003e24 hours\u003c\/strong\u003e for inquiries. This efficiency is backed by a customer service satisfaction rate of \u003cstrong\u003e87%\u003c\/strong\u003e, as indicated in their 2023 annual report. The firm employs a multi-channel approach, using phone, email, and social media platforms to connect with customers effectively.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eYear\u003c\/th\u003e\n        \u003cth\u003eResponse Time (Hours)\u003c\/th\u003e\n        \u003cth\u003eCustomer Service Satisfaction Rate (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e30\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e85\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e24\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e87\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2023\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e20\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e90\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eLoyalty Programs\u003c\/h3\u003e\n\n\u003cp\u003eThe loyalty programs implemented by Tianjin Chase Sun are designed to enhance customer retention and increase repeat purchases. In 2022, the company launched a points-based loyalty program, which has already attracted over \u003cstrong\u003e10,000\u003c\/strong\u003e active members within its first year. According to their data, members of the loyalty program increased their average annual purchase by \u003cstrong\u003e20%\u003c\/strong\u003e compared to non-members. The company also reports that loyalty program members contribute to approximately \u003cstrong\u003e30%\u003c\/strong\u003e of total sales revenue.\u003c\/p\u003e\n\n\u003cp\u003eThe success of these initiatives is further highlighted by a revenue growth of \u003cstrong\u003e15%\u003c\/strong\u003e reported in Q2 2023, which can be attributed to the enhanced customer engagement through these loyalty schemes.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTianjin Chase Sun Pharmaceutical Co.,Ltd - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eThe distribution and communication strategies employed by Tianjin Chase Sun Pharmaceutical Co., Ltd. are critical to delivering its value proposition effectively to customers. The company utilizes a multifaceted approach that includes wholesale distributors, online platforms, and retail pharmacies.\u003c\/p\u003e\n\n\u003ch3\u003eWholesale Distributors\u003c\/h3\u003e\n\n\u003cp\u003eTianjin Chase Sun Pharmaceutical has established a robust network of wholesale distributors to expand its market reach. As of 2023, the company collaborates with over \u003cstrong\u003e200\u003c\/strong\u003e wholesale distributors across various provinces in China. This extensive network enables efficient distribution and access to a broad customer base.\u003c\/p\u003e\n\n\u003ctable\u003e\n   \u003ctr\u003e\n      \u003cth\u003eDistributor Region\u003c\/th\u003e\n      \u003cth\u003eNumber of Distributors\u003c\/th\u003e\n      \u003cth\u003eAnnual Sales Volume (CNY)\u003c\/th\u003e\n   \u003c\/tr\u003e\n   \u003ctr\u003e\n      \u003ctd\u003eNorth China\u003c\/td\u003e\n      \u003ctd\u003e80\u003c\/td\u003e\n      \u003ctd\u003e500 million\u003c\/td\u003e\n   \u003c\/tr\u003e\n   \u003ctr\u003e\n      \u003ctd\u003eEast China\u003c\/td\u003e\n      \u003ctd\u003e60\u003c\/td\u003e\n      \u003ctd\u003e400 million\u003c\/td\u003e\n   \u003c\/tr\u003e\n   \u003ctr\u003e\n      \u003ctd\u003eSouth China\u003c\/td\u003e\n      \u003ctd\u003e40\u003c\/td\u003e\n      \u003ctd\u003e300 million\u003c\/td\u003e\n   \u003c\/tr\u003e\n   \u003ctr\u003e\n      \u003ctd\u003eWest China\u003c\/td\u003e\n      \u003ctd\u003e20\u003c\/td\u003e\n      \u003ctd\u003e200 million\u003c\/td\u003e\n   \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis dependence on wholesale distributors contributes significantly to the company's revenue, with wholesale sales accounting for approximately \u003cstrong\u003e60%\u003c\/strong\u003e of total revenues in 2022, amounting to around \u003cstrong\u003e1.4 billion CNY\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Platforms\u003c\/h3\u003e\n\n\u003cp\u003eIn line with the growing trend of digitalization, Tianjin Chase Sun Pharmaceutical has also focused on enhancing its online presence. The company utilizes e-commerce platforms to reach a wider audience. As of late 2022, it reported a \u003cstrong\u003e35%\u003c\/strong\u003e increase in online sales, reaching approximately \u003cstrong\u003e700 million CNY\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe company is active on several platforms, including:\u003c\/p\u003e\n\n\u003cul\u003e\n   \u003cli\u003eJD.com\u003c\/li\u003e\n   \u003cli\u003eAlibaba\u003c\/li\u003e\n   \u003cli\u003eAmazon China\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe online channel represents a growing segment of the company’s strategy, accounting for about \u003cstrong\u003e25%\u003c\/strong\u003e of total revenue, which is estimated at \u003cstrong\u003e2.8 billion CNY\u003c\/strong\u003e for fiscal year 2022.\u003c\/p\u003e\n\n\u003ch3\u003eRetail Pharmacies\u003c\/h3\u003e\n\n\u003cp\u003eTianjin Chase Sun Pharmaceutical has a strong foothold in the retail pharmacy sector as well. The company’s products are available in over \u003cstrong\u003e5,000\u003c\/strong\u003e retail pharmacies across the country. Retail sales from these pharmacies contribute significantly to revenues, with approximately \u003cstrong\u003e50%\u003c\/strong\u003e of sales coming from this channel.\u003c\/p\u003e\n\n\u003ctable\u003e\n   \u003ctr\u003e\n      \u003cth\u003ePharmacy Type\u003c\/th\u003e\n      \u003cth\u003eNumber of Pharmacies\u003c\/th\u003e\n      \u003cth\u003eSales Volume (CNY)\u003c\/th\u003e\n   \u003c\/tr\u003e\n   \u003ctr\u003e\n      \u003ctd\u003eIndependent Pharmacies\u003c\/td\u003e\n      \u003ctd\u003e3,000\u003c\/td\u003e\n      \u003ctd\u003e800 million\u003c\/td\u003e\n   \u003c\/tr\u003e\n   \u003ctr\u003e\n      \u003ctd\u003eChain Pharmacies\u003c\/td\u003e\n      \u003ctd\u003e2,000\u003c\/td\u003e\n      \u003ctd\u003e1.2 billion\u003c\/td\u003e\n   \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOverall, retail pharmacies accounted for roughly \u003cstrong\u003e40%\u003c\/strong\u003e of the company's total revenue, equating to about \u003cstrong\u003e1 billion CNY\u003c\/strong\u003e in 2022. This sector remains crucial for building brand awareness and customer loyalty.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTianjin Chase Sun Pharmaceutical Co.,Ltd - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eTianjin Chase Sun Pharmaceutical Co., Ltd. operates across various customer segments, focusing on delivering specialized pharmaceutical products and services. The primary customer segments include healthcare providers, retail pharmacists, and direct consumers.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Providers\u003c\/h3\u003e\n\n\u003cp\u003eThe healthcare providers include hospitals, clinics, and medical institutions that require pharmaceutical products for patient care. As of 2022, there were approximately \u003cstrong\u003e38,000 hospitals\u003c\/strong\u003e in China, with a growing demand for specialized pharmaceutical solutions. Chase Sun Pharmaceutical has established partnerships with over \u003cstrong\u003e5,000 healthcare institutions\u003c\/strong\u003e, ensuring a steady supply of essential medications.\u003c\/p\u003e\n\n\u003ch3\u003eRetail Pharmacists\u003c\/h3\u003e\n\n\u003cp\u003eRetail pharmacists play a crucial role in the distribution of pharmaceutical products to the consumer market. The retail pharmacy market in China was valued at around \u003cstrong\u003eUSD 40 billion\u003c\/strong\u003e in 2022 and is projected to reach \u003cstrong\u003eUSD 60 billion\u003c\/strong\u003e by 2025, driven by an increase in healthcare consumption and the rising prevalence of chronic diseases. Chase Sun Pharmaceutical collaborates with more than \u003cstrong\u003e20,000 retail pharmacies\u003c\/strong\u003e to enhance the availability of its products.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Consumers\u003c\/h3\u003e\n\n\u003cp\u003eThe direct consumer segment includes individual patients who purchase medications either through retail pharmacies or online platforms. In 2021, the number of online pharmacy users in China surpassed \u003cstrong\u003e400 million\u003c\/strong\u003e, with projections indicating growth to \u003cstrong\u003e600 million\u003c\/strong\u003e by 2025. Chase Sun Pharmaceutical addresses this growing demand by offering a user-friendly online platform that contributes to its sales, which reached approximately \u003cstrong\u003eRMB 1.5 billion\u003c\/strong\u003e (about USD 230 million) in direct consumer sales in 2022.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer Segment\u003c\/th\u003e\n\u003cth\u003eMarket Size (2022)\u003c\/th\u003e\n\u003cth\u003eProjected Growth (2025)\u003c\/th\u003e\n\u003cth\u003ePartnerships\/Reach\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Providers\u003c\/td\u003e\n\u003ctd\u003eUSD 10 billion\u003c\/td\u003e\n\u003ctd\u003eUSD 15 billion\u003c\/td\u003e\n\u003ctd\u003e5,000+ healthcare institutions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail Pharmacists\u003c\/td\u003e\n\u003ctd\u003eUSD 40 billion\u003c\/td\u003e\n\u003ctd\u003eUSD 60 billion\u003c\/td\u003e\n\u003ctd\u003e20,000+ retail pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Consumers\u003c\/td\u003e\n\u003ctd\u003eRMB 1.5 billion (USD 230 million)\u003c\/td\u003e\n\u003ctd\u003eRMB 2.5 billion (USD 385 million)\u003c\/td\u003e\n\u003ctd\u003e400 million online users\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTianjin Chase Sun Pharmaceutical Co.,Ltd - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003eThe cost structure of Tianjin Chase Sun Pharmaceutical Co., Ltd is comprised of several critical components that impact their overall operational efficiency and profitability.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing expenses\u003c\/h3\u003e\n\n\u003cp\u003eThe manufacturing expenses encompass costs related to the production of pharmaceutical products, including raw materials, labor, and overhead costs. In 2022, Tianjin Chase Sun Pharmaceutical reported manufacturing costs amounting to approximately \u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e. The breakdown of these expenses is as follows:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCost Element\u003c\/th\u003e\n    \u003cth\u003eAmount (¥)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRaw Materials\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e¥600 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLabor Costs\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e¥300 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOverhead Costs\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e¥300 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eR\u0026amp;D investments\u003c\/h3\u003e\n\n\u003cp\u003eResearch and Development (R\u0026amp;D) investments are vital for pharmaceutical companies to innovate and enhance their product lines. In the fiscal year 2022, Tianjin Chase Sun allocated about \u003cstrong\u003e¥400 million\u003c\/strong\u003e for R\u0026amp;D activities. This represented approximately \u003cstrong\u003e8%\u003c\/strong\u003e of their total revenue. The key areas of focus included:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eDevelopment of new drug formulations\u003c\/li\u003e\n  \u003cli\u003eClinical trials\u003c\/li\u003e\n  \u003cli\u003eQuality improvement processes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRegulatory compliance costs\u003c\/h3\u003e\n\n\u003cp\u003eRegulatory compliance is critical in the pharmaceutical industry, involving expenses to meet local and international health regulations. For the year ending December 2022, the company incurred regulatory compliance costs estimated at \u003cstrong\u003e¥150 million\u003c\/strong\u003e. This includes:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCompliance Activity\u003c\/th\u003e\n    \u003cth\u003eCost (¥)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQuality Assurance Audits\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e¥70 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLicensing Fees\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e¥40 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eConsultation for Regulatory Affairs\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e¥40 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTianjin Chase Sun Pharmaceutical Co.,Ltd - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003eTianjin Chase Sun Pharmaceutical Co., Ltd. operates with diverse revenue streams that contribute significantly to its overall financial performance. The company focuses primarily on pharmaceutical manufacturing, with its revenue model encompassing various methods of generating income.\u003c\/p\u003e\n\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\n\u003cp\u003eProduct sales represent a substantial portion of Tianjin Chase Sun's revenue. The company's core products include active pharmaceutical ingredients (APIs) and finished dosage forms. In 2022, Tianjin Chase Sun reported total revenue of approximately \u003cstrong\u003eRMB 2.5 billion\u003c\/strong\u003e, with product sales accounting for around \u003cstrong\u003e85%\u003c\/strong\u003e of this total.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a breakdown of major product categories and their contributions to revenue:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct Category\u003c\/th\u003e\n\u003cth\u003eRevenue (RMB Billion)\u003c\/th\u003e\n\u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Pharmaceutical Ingredients (APIs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e48%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinished Dosage Forms\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e44%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther Pharmaceutical Products\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eLicensing Agreements\u003c\/h3\u003e\n\n\u003cp\u003eTianjin Chase Sun also engages in licensing agreements to enhance its revenue streams. These agreements typically involve partnerships with larger pharmaceutical firms to develop and market specialty drugs. In 2022, the company generated approximately \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e through licensing deals, representing about \u003cstrong\u003e6%\u003c\/strong\u003e of total revenue.\u003c\/p\u003e\n\n\u003cp\u003eThe following table outlines details of key licensing agreements:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner Company\u003c\/th\u003e\n\u003cth\u003eProduct Licensed\u003c\/th\u003e\n\u003cth\u003eRevenue from Licensing (RMB Million)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXYZ Pharma\u003c\/td\u003e\n\u003ctd\u003eNovel Antibiotic\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eABC Biotech\u003c\/td\u003e\n\u003ctd\u003eBiologic Drug\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e45\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMNO Therapeutics\u003c\/td\u003e\n\u003ctd\u003eOncology Treatment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e45\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eGovernment Contracts\u003c\/h3\u003e\n\n\u003cp\u003eA significant revenue stream for Tianjin Chase Sun comes from government contracts, particularly in the public health sector. The company has secured multiple contracts with local and national governments for the supply of essential medicines and likely benefits from favorable pricing due to its strategic partnerships. In 2022, government contracts contributed around \u003cstrong\u003eRMB 600 million\u003c\/strong\u003e, approximately \u003cstrong\u003e24%\u003c\/strong\u003e of the total revenue.\u003c\/p\u003e\n\n\u003cp\u003eDetails of government contracts are summarized in the following table:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eContract Type\u003c\/th\u003e\n\u003cth\u003ePartner\/Agency\u003c\/th\u003e\n\u003cth\u003eRevenue (RMB Million)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic Health Supply\u003c\/td\u003e\n\u003ctd\u003eMinistry of Health\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e350\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccination Programs\u003c\/td\u003e\n\u003ctd\u003eLocal Government\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e200\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch Grants\u003c\/td\u003e\n\u003ctd\u003eNational Science Foundation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45675552440469,"sku":"300026sz-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/300026sz-business-model-canvas.png?v=1739123044","url":"https:\/\/dcf-analysis.com\/products\/300026sz-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}